 BOSTON, Jan. 9, 2023 PRNewswire MedTherapy Biotechnology Inc., a privately held CAR-T cell cancer gene therapy biotechnology company, announced that its technology could potentially reduce the time and cost to manufacture CAR-T cell cancer gene therapy to a fraction, approximately by seventy percent. Its clinical development plan and strategies are being presented at the ...... 